ClinicalTrials.gg
CompletedNCT05342597Updated Jul 15, 2026Results posted

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

A Phase 1 interventional study of MT-1186 in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shionogi · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Jun 2019, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

To evaluate the effect of food on the pharmacokinetics of oral edaravone in healthy adult subjects. In this study, we determined 5 different dietary conditions including 4 different meal contents and fasting condition.

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who meet all of the following criteria and who have the capability of giving will be included in the study.

    1. Healthy adult male or female volunteers
    2. Japanese
    3. Subjects aged between 20 and 45 years at the time of informed consent
    4. Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Subjects who met any of the following exclusion criteria between screening and product administration were excluded from the study:

    1. Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study
    2. History of drug or food allergies
    3. History of alcohol or drug abuse or dependence
    4. (BMI) of \< 18.0 or > 30.0, or a body weight of \< 50 kg [BMI formula: body weight (kg)/height (m)2, rounded to one decimal place]
    5. Positive test for any of the following at screening: surface (HBs) antigen, serological test for syphilis, virus (HCV) antibody, or (HIV) antigen/antibody
    6. Any 12-lead abnormality or interval (QTc) using Fridericia's formula (QTcF) interval ≥ 450 msec
    7. Blood donation or sampling with a total volume of ≥ 400 mL within 12 weeks, ≥ 200 mL within 4 weeks, or ≥ 800 mL within one year before providing
    8. Blood component donation or blood sampling within 2 weeks before providing informed consent
    9. Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs (except for appendectomy and herniotomy)
    10. Female subjects who do not agree to use an effective method of from screening or 2 weeks before the start of investigational product administration, whichever comes earlier, to 14 days after the completion (or discontinuation) of investigational product administration. Male subjects who do not agree to use an effective method of contraception from the start of investigational product administration to 14 days after the completion (or discontinuation) of investigational product administration
    11. Subjects who have previously received edaravone
    12. Subjects who have participated in another clinical study and received an investigational product within 12 weeks before providing informed consent
    13. Subjects who have used any drugs other than the single use of acetylsalicylic acid within 7 days before the initiation of investigational product administration
    14. Use of any nutritional supplement(s) within 7 days before the initiation of investigational product administration
    15. Use of alcohol or any products containing xanthin or caffeine within 24 hours before screening and visit on Day -1
    16. Use of grapefruit, grapefruit juice, or any processed food(s) containing these substances within 24 hours before screening and visit on Day -1
    17. Use of any tobacco or nicotine-containing product(s) within 24 hours before screening and visit on Day -1
    18. Female subjects who have a positive pregnancy test at screening and on Day -1, are pregnant or breast feeding, or plan to get pregnant during the study
    19. Subjects judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Group A

    A single oral dose of MT-1186 with fasted condition in period 1, meal 1 condition in period 2, meal 2 condition in period 3, meal 3 condition in period 4, and meal 4 condition in period 5.

    Drug: MT-1186

  • Experimental
    Group B

    A single oral dose of MT-1186 with meal 1 condition in period 1, meal 2 condition in period 2, meal 3 condition in period 3, fasted condition in period 4, and meal 4 condition in period 5.

    Drug: MT-1186

  • Experimental
    Group C

    A single oral dose of MT-1186 with meal 2 condition in period 1, meal 3 condition in period 2, fasted condition in period 3, meal 1 condition in period 4, and meal 4 condition in period 5.

    Drug: MT-1186

  • Experimental
    Group D

    A single oral dose of MT-1186 with meal 3 condition in period 1, fasted condition in period 2, meal 1 condition in period 3, meal 2 in period 4, and meal 4 condition in period 5.

    Drug: MT-1186

Interventions

  • A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.

    Also known as: Edaravone

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  2. Maximum Plasma Concentration (Cmax) of Edaravone

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  3. AUC0-inf of Sulfate Conjugate and Glucuronide Conjugate

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  4. Cmax of Sulfate Conjugate and Glucuronide Conjugate

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  5. Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  6. Terminal Elimination Half-life (t1/2) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  7. Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  8. Mean Residence Time (MRT) of Unchanged Edaravone

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  9. Apparent Total Clearance (CL/F) of Unchanged Edaravone

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  10. Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  11. Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone

    Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration

  12. Cumulative Urinary Excretion Amount (Ae 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate

    Time frame: Day 1 to 9, Day 24 to 26

  13. Urinary Excretion Ratio (Ae% 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate

    Time frame: Day 1 to 9, Day 24 to 26

  14. Renal Clearance (CLr) of Unchanged Edaravone

    Time frame: Day 1 to 9, Day 24 to 26

Secondary outcomes

  1. Number of Participants With Adverse Events and Adverse Drug Reactions

    Time frame: Day 1 to Day 31

07

Results

Posted Jan 5, 2024

Participant flow

Period 1
Participant flow — Period 1
MilestoneGroup AGroup BGroup CGroup D
Started4444
Completed4444
Not completed0000
Period 2
Participant flow — Period 2
MilestoneGroup AGroup BGroup CGroup D
Started4444
Completed4444
Not completed0000
Period 3
Participant flow — Period 3
MilestoneGroup AGroup BGroup CGroup D
Started4444
Completed4444
Not completed0000
Period 4
Participant flow — Period 4
MilestoneGroup AGroup BGroup CGroup D
Started4444
Completed4444
Not completed0000
Period 5
Participant flow — Period 5
MilestoneGroup AGroup BGroup CGroup D
Started4444
Completed4444
Not completed0000

Outcome measures

PrimaryArea Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · ng·h/mL
Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone
ng·h/mLEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone2165 ± 6732209 ± 6582073 ± 6411955 ± 5231717 ± 463
Statistical analysis
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 8 Hours After a High-fat Meal · ANOVA · Ls mean ratio: 1.025 · 90% CI 0.931 to 1.128
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 4 Hours After a Low-fat Meal · ANOVA · Ls mean ratio: 0.959 · 90% CI 0.871 to 1.056
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 2 Hours After a Light Meal · ANOVA · Ls mean ratio: 0.910 · 90% CI 0.827 to 1.002
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 2 Hours After a Low-fat Meal · ANOVA · Ls mean ratio: 0.801 · 90% CI 0.712 to 0.901
PrimaryMaximum Plasma Concentration (Cmax) of Edaravone
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Edaravone
ng/mLEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Maximum Plasma Concentration (Cmax) of Edaravone2318 ± 12292525 ± 13372020 ± 11141898 ± 865.91276 ± 805.6
Statistical analysis
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 8 Hours After a High-fat Meal · ANOVA · Ls mean ratio: 1.083 · 90% CI 0.821 to 1.429
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 4 Hours After a Low-fat Meal · ANOVA · Ls mean ratio: 0.872 · 90% CI 0.661 to 1.150
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 2 Hours After a Light Meal · ANOVA · Ls mean ratio: 0.820 · 90% CI 0.621 to 1.082
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 2 Hours After a Low-fat Meal · ANOVA · Ls mean ratio: 0.536 · 90% CI 0.362 to 0.794
PrimaryAUC0-inf of Sulfate Conjugate and Glucuronide Conjugate
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · ng·h/mL
AUC0-inf of Sulfate Conjugate and Glucuronide Conjugate
ng·h/mLEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Sulfate conjugate24519 ± 724325724 ± 772924671 ± 607725903 ± 865726293 ± 10355
Glucuronide conjugate4054 ± 7913895 ± 7964109 ± 8913914 ± 8414325 ± 1054
PrimaryCmax of Sulfate Conjugate and Glucuronide Conjugate
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · ng/mL
Cmax of Sulfate Conjugate and Glucuronide Conjugate
ng/mLEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Sulfate conjugate8456 ± 20419024 ± 24308629 ± 19608665 ± 23627986 ± 2288
Glucuronide conjugate2283 ± 496.22209 ± 645.92283 ± 486.72141 ± 548.12031 ± 608.9
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Median · h
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Unchanged edaravone0.38 (0.25 to 0.50)0.25 (0.08 to 0.75)0.50 (0.25 to 0.75)0.38 (0.25 to 1.00)0.50 (0.25 to 1.50)
Sulfate conjugate0.75 (0.50 to 0.75)0.63 (0.50 to 1.00)0.75 (0.50 to 1.00)0.75 (0.50 to 1.50)1.00 (0.75 to 1.50)
Glucuronide conjugate0.50 (0.50 to 1.00)0.50 (0.50 to 1.00)0.75 (0.50 to 1.00)0.50 (0.50 to 1.50)0.75 (0.50 to 1.00)
PrimaryTerminal Elimination Half-life (t1/2) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · h
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Unchanged edaravone8.17 ± 2.297.38 ± 1.979.05 ± 5.077.31 ± 4.311.25 ± 8.35
Sulfate conjugate6.32 ± 1.857.16 ± 2.525.85 ± 1.186.25 ± 1.694.91 ± 1.02
Glucuronide conjugate4.12 ± 0.344.07 ± 0.414.12 ± 0.464.03 ± 0.73.67 ± 0.34
PrimaryApparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · 1/h
Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
1/hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Unchanged edaravone0.0931 ± 0.03430.0999 ± 0.02480.1010 ± 0.06450.1108 ± 0.03300.0864 ± 0.0435
Sulfate conjugate0.1164 ± 0.02490.1062 ± 0.03000.1221 ± 0.01950.1172 ± 0.02460.1463 ± 0.0266
Glucuronide conjugate0.1690 ± 0.01250.1720 ± 0.01620.1699 ± 0.01730.1762 ± 0.02540.1905 ± 0.0176
PrimaryMean Residence Time (MRT) of Unchanged Edaravone
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · h
Mean Residence Time (MRT) of Unchanged Edaravone
hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Mean Residence Time (MRT) of Unchanged Edaravone2.35 ± 0.522.19 ± 0.492.34 ± 0.442.32 ± 0.543.55 ± 0.87
PrimaryApparent Total Clearance (CL/F) of Unchanged Edaravone
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · L/h
Apparent Total Clearance (CL/F) of Unchanged Edaravone
L/hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Apparent Total Clearance (CL/F) of Unchanged Edaravone53.0 ± 16.351.4 ± 14.455.1 ± 16.957.9 ± 17.665.4 ± 17.3
PrimaryApparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · L
Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone
LEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone608 ± 247530 ± 156646 ± 239585 ± 305993 ± 666
PrimaryApparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
Time frame:
Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Reported as:
Mean · L
Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
LEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone126.4 ± 57.2114.2 ± 46.7128.6 ± 41.6136.1 ± 59.0231.4 ± 84.0
PrimaryCumulative Urinary Excretion Amount (Ae 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame:
Day 1 to 9, Day 24 to 26
Reported as:
Mean · mg
Cumulative Urinary Excretion Amount (Ae 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
mgEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Unchanged edaravone0.819 ± 0.3491.609 ± 2.6300.977 ± 0.4060.988 ± 0.9651.302 ± 2.086
Sulfate conjugate13.87 ± 12.6213.10 ± 12.6113.13 ± 13.9913.14 ± 10.968.89 ± 9.50
Glucuronide conjugate144.6 ± 19.9146.8 ± 20.5144.0 ± 18.4153.2 ± 22.6160.2 ± 44.8
PrimaryUrinary Excretion Ratio (Ae% 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame:
Day 1 to 9, Day 24 to 26
Reported as:
Mean · % of dose
Urinary Excretion Ratio (Ae% 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
% of doseEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Unchanged edaravone0.780 ± 0.3491.533 ± 2.5050.931 ± 0.3860.941 ± 0.9191.240 ± 1.986
Sulfate conjugate9.08 ± 8.278.58 ± 8.268.60 ± 9.178.61 ± 7.185.82 ± 6.22
Glucuronide conjugate68.7 ± 9.569.7 ± 9.768.4 ± 8.872.8 ± 10.776.1 ± 21.3
PrimaryRenal Clearance (CLr) of Unchanged Edaravone
Time frame:
Day 1 to 9, Day 24 to 26
Reported as:
Mean · L/h
Renal Clearance (CLr) of Unchanged Edaravone
L/hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Renal Clearance (CLr) of Unchanged Edaravone0.419 ± 0.2710.818 ± 1.4130.535 ± 0.3330.545 ± 0.5350.871 ± 1.582
SecondaryNumber of Participants With Adverse Events and Adverse Drug Reactions
Time frame:
Day 1 to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Adverse Drug Reactions
ParticipantsEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
Number of Participants with Adverse events00100
Number of Participants with adverse drug reactions00000

Adverse events

Collected over Day 1 to Day 31. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Edaravone Single Dose Under Fasting Condition0/16 (0%)0/16 (0%)0/16 (0%)
Edaravone Single Dose 8 Hours After a High-fat Meal0/16 (0%)0/16 (0%)0/16 (0%)
Edaravone Single Dose 4 Hours After a Low-fat Meal0/16 (0%)0/16 (0%)1/16 (6.3%)
Edaravone Single Dose 2 Hours After a Light Meal0/16 (0%)0/16 (0%)0/16 (0%)
Edaravone Single Dose 2 Hours After a Low-fat Meal0/16 (0%)0/16 (0%)0/16 (0%)
Most frequent other events
Most frequent other events
EventEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 8 Hours After a High-fat MealEdaravone Single Dose 4 Hours After a Low-fat MealEdaravone Single Dose 2 Hours After a Light MealEdaravone Single Dose 2 Hours After a Low-fat Meal
UrticariaSkin and subcutaneous tissue disorders0/160/161/160/160/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group AGroup BGroup CGroup DTotal
<=18 years00000
Between 18 and 65 years444416
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BGroup CGroup DTotal
Female11114
Male333312
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group AGroup BGroup CGroup DTotal
American Indian or Alaska Native00000
Asian444416
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Investigational site
    Tokyo, Japan
09

References and documents

Publications

  • Shimizu H, Nishimura Y, Shiide Y, Akimoto M, Matsuda H, Kato Y, Hirai M. Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Clin Ther. 2022 Dec;44(12):1552-1565. doi: 10.1016/j.clinthera.2022.10.001. Epub 2022 Nov 12. PubMed 36376130 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Jul 2019, 1 month.

Results were first posted in Jan 2024, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
Apr 22, 2022
StartActual
Jun 10, 2019
Primary completionActual
Jul 24, 2019
CompletionActual
Jul 24, 2019
Results first posted
Jan 5, 2024
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05342597
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Apr 22, 2022
Start date
Jun 10, 2019
Primary completion
Jul 24, 2019
Completion
Jul 24, 2019
Results posted
Jan 5, 2024
Last update
Jul 15, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion